Bigul

PIRAMAL ENTERPRISES LTD. - 500302 - Announcement under Regulation 30 (LODR)-Meeting Updates

Kindly refer to our letter dated 20th June, 2020 on the subject. Pursuant to Regulation 30 of the Listing Regulations, we write to inform you that at the Meeting of Administrative Committee of the Board of Directors held today, the Committee approved the issue of secured, rated, unlisted, redeemable Non-Convertible Bonds ('Bonds') on private placement basis as per the details mentioned in Annexure A. The meeting commenced at 3:45 p.m. and concluded at 4:15 p.m. Kindly take the above on record and oblige.
23-06-2020
Bigul

PIRAMAL ENTERPRISES LTD. - 500302 - Intimation Under Regulation 57 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Intimation under Regulation 57 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
23-06-2020
Bigul

PIRAMAL ENTERPRISES LTD. - 500302 - Intimation Under Regulation 57 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Intimation under Regulation 57 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
22-06-2020
Bigul

PIRAMAL ENTERPRISES LTD. - 500302 - Announcement under Regulation 30 (LODR)-Meeting Updates

Pursuant to Regulations 29 & 50 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we write to inform you that a meeting of the Administrative Committee of the Board of Directors of the Company will be held on Tuesday, 23rd June, 2020, to consider and approve the issue of secured, rated, unlisted non-convertible debentures on private placement basis amounting up to Rs. 2,700 crores. Kindly take the above on record and oblige.
20-06-2020
Bigul

Piramal Pharma to acquire G&W; Lab's manufacturing unit for $17.5 million

Piramal Enterprises Ltd's (PEL) Pharma Solutions business on Saturday said it has entered into an agreement with G&W Laboratories Inc. to acquire
20-06-2020
Bigul

PIRAMAL ENTERPRISES LTD. - 500302 - Announcement under Regulation 30 (LODR)-Acquisition

In accordance with the provisions of Regulation 30 of the SEBI Listing Regulations and SEBI's circular no. CIR/CFD/CMD/4/2015 dated September 9, 2015, we wish to inform you that the Company's Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), has entered into an agreement with G&W; Laboratories Inc. to acquire its solid oral dosage drug product manufacturing facility located in Sellersville, Pennsylvania. The transaction closure is subject to customary pre-closing conditions. According to the terms of the agreement, Piramal Enterprises Limited ('PEL'), through one of its Affiliates, would acquire at closing a 100% stake in G&W; PA Laboratories LLC ('G&W; PA') in an all-cash deal for a total consideration of USD 17.5 million. G&W; PA was formed on November 5, 2014. The transaction is not subject to any regulatory approvals. No related party of PEL has any interest in G&W; PA.
20-06-2020
Bigul

PIRAMAL ENTERPRISES LTD. - 500302 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
17-06-2020
Bigul

PIRAMAL ENTERPRISES LTD. - 500302 - Compliances-Reg. 57 (1) - Certificate of interest payment/Principal in case of NCD

Intimation under Regulation 57 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
17-06-2020
Bigul

PIRAMAL ENTERPRISES LTD. - 500302 - Compliances-Reg.24(A)-Annual Secretarial Compliance

Annual Secretarial Compliance Report for the year ended 31st March, 2020
09-06-2020
Bigul

PIRAMAL ENTERPRISES LTD. - 500302 - Newspaper Advertisement For Transfer Of Equity Shares Of The Company To Investor Education And Protection Fund (IEPF) Authority

Newspaper advertisement for transfer of Equity Shares of the Company to Investor Education and Protection Fund (IEPF) Authority
05-06-2020
Next Page
Close

Let's Open Free Demat Account